The planned inclusion aims to enhance share tradability and facilitate future access to XETRA trading.
London (UK), October 21, 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage biopharmaceutical company pioneering novel anti-cancer therapies targeting the tumor microenvironment, announces that it intends to apply for its shares to be included in the open market of the Düsseldorf Stock Exchange, sub-segment Primary Market. The inclusion of the shares in the open market of the Düsseldorf Stock Exchange (Primary Market), in addition to the existing listings on the open markets of the Hamburg, Stuttgart, and Berlin stock exchanges, is intended to further increase the tradability of the shares for the benefit of investors, in particular through the subsequent inclusion of the shares in XETRA trading. As things stand at present, the inclusion of the shares in the open market of the Düsseldorf Stock Exchange (Primary Market) is planned for the beginning of November. The inclusion is subject to the approval of the Düsseldorf Stock Exchange and therefore cannot be predicted with certainty at this stage.
“Our goal is to make Vidac Pharma’s shares increasingly accessible to investors,” said Dr. Max Herzberg, CEO of Vidac Pharma Holding PLC. “The planned inclusion in Düsseldorf and potential XETRA trading are important steps in strengthening liquidity in the share trade and broadening our investor base.”
For more information please contact:
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.
Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.